Synergy Pharmaceuticals Phase IIb/III plecanatide study completes enrollment

Synergy Pharmaceuticals announced that its Phase IIb/III plecanatide study in chronic idiopathic constipation, or CIC, achieved its enrollment target of 880 patients on August 13. Sites have been notified that screening will close August 16th and enrollment will close at the end of the month. Synergy designed the trial to include exploration of the low end of the plecanatide dose range in CIC, which is consistent with discussions Synergy has had with FDA. Synergy anticipates topline data being released by year end.